STOCKHOLDERSS EQUITY (DEFICIT)

6 Months Ended

Sep. 30, 2024

STOCKHOLDERSS EQUITY (DEFICIT)

STOCKHOLDERS'S EQUITY (DEFICIT)

NOTE 7 – STOCKHOLDERS’S EQUITY (DEFICIT)

The Company has 2,000,000,000 shares of $0.001 par value common stock authorized and 10,000,000 shares of $0.001 par value preferred stock authorized.

On June 13, 2023, we issued 13,500,000 shares of common stock to EMC2 Capital LLC following the cashless exercise of their 15,000,000 Warrants issued in August 2021.

On June 13, 2023, we issued 476,000 shares of common stock to Alison Rose Burgess as settlement of a £125,000 Sterling loan under the terms and conditions of the loan dated 21 September 2021.

On June 13, 2023, we issued 5,000,000 shares of common stock to Alinova Biosciences Ltd as part payment of consideration for the acquisition of intellectual property.

On June 13, 2023, we issued 5,999,900 shares of common stock to Long Eight Limited as part payment of consideration for services received by Green Ocean Administration Limited.

On June 13, 2023, we issued 10,088,100 shares of common stock to Warren Law Group to be held in escrow as potential part payment for services received from Bridgeway Capital Partners LLC, Bridgeway Capital Partners II LLC and Entoro Securities LLC.

On June 14, 2023, we issued 9,000,000 shares of common stock to our Directors as payment for their services as Directors. 

On September 8, 2023, the Company entered into an Agreement to Return Assets and Shares with C2 Wellness Corp. As part of the agreement, the company received 29,015,993 shares of ABTI stock (24,000,000 shares originally issued and 5,015,996 shares additionally issued) and sold all assets related to the acquisition, resulting in a write-off of $12,000,000 in intangibles.

On October 16, 2023, the Company issued 587,499,996 shares in exchange of forgiveness of debt of approximately $2.35 million outstanding. The exchange resulted in a loss on exchange of $406,575.

On December 21, 2023, the Company issued 17,131,001 shares in exchange for services provided for the company for the period ended June 30, 2024, valued at $61,672 at the date of issuance.

On May 9, 2024, 2024, the Company issued a total 39,000,000 shares to Long Eight Limited in exchange for services provided to the Company at a price per share of $0.0037.

On May 16, 2024, the Company issued a total 18,000,000 shares to Long Eight Limited in exchange for services provided to the Company at a price per share of $0.0033.

On May 9, 2024, the Company issued a total of 7,812,500 shares to Guy Webber in lieu of services provided to the Company as per his employment contract, at a price per share of $0.0037.

On May 9, 2024, the Company issued a total of 5,000,000 shares to Nathan Thompson in lieu of payment for Director Services provided to the Company for the period July 1, 2023 to March 31, 2024, at a price per share of $0.0037.

On May 9, 2024, the Company issued a total of 5,000,000 shares to Ning Qu in lieu of payment for Director Services provided to the Company for the period July 01, 2023 to March 31, 2024, at a price per share of $0.0037.

On May 9, 2024, the Company issued a total of 5,000,000 shares to Michael Hunter Land in lieu of payment for Director Services provided to the Company for the period July 01, 2023 to March 31, 2024 at a price per share of $0.0037.

On May 9, 2024, the Company issued a total of 5,000,000 shares to Daniel Reshef in lieu of payment for Director Services provided to the Company for the period July 01, 2023 to March 31, 2024 at a price per share of $0.0037.

On May 16, 2024, Phytanix Bio authorized the expansion of its share capital to 10,000,000 common shares and 10,000 Preferred shares and authorized the acquisition of 100% of the share capital of ABTI Pharma Ltd by Phytanix Bio for the consideration of 5,000,000 Phytanix Bio shares. Accordingly, on May 16, 2024, pursuant to the written consent to action without a meeting of the directors of Phytanix Bio, Phytanix Bio issued 5,000,000 shares of its common stock to acquire the common stock of ABTI Pharma and its subsidiaries for cash of $200.  The cash received was recorded as additional paid in capital on the statement of stockholders’ equity.

Pursuant to an Exchange Agreement (the “Agreement”) entered into on May 16, 2024, between the Company and EMC2 Capital LLC, a shareholder of Alterola Biotech, Phytanix Bio issued 800,000 shares of its common stock and 17,000 shares of its Series A preferred stock to EMC2 Capital, LLC in exchange for the return of 13,500,000 common shares of the Company. Accordingly, the Company ownership of Phytanix Bio decreased from 100% to 86.2%. As of the date of this report, the 13,500,000 shares of common stock had not been received or cancelled. This was recorded as additional paid in capital on the statement of stockholders’ equity.

During the year ended March 31, 2024, the Company reviewed the cumulative translation adjustment recorded on the financial statements and made corrections to the amount recorded for the year ended March 31, 2023 as discussed in the restatement footnote (Note 2) contained in the Company’s annual report on Form 10-K for the year ended March 31, 2024. The updated number was recorded as $67,873.

The Company has 1,467,475,449 and 1,382,662,949 shares of common stock issued and outstanding as of September 30, 2024 and March 31, 2024, respectively. There are no shares of preferred stock issued and outstanding as of September 30, 2024 and March 31, 2024.  The Company had 778,031,952 shares of common stock issued and outstanding as of September 30, 2023 and 807,047,948 shares of common stock issued and outstanding as of March 31, 2023. There were no shares of preferred stock issued and outstanding as of September 30, 2023 and March 31, 2023.